Global Transient Ischemic Attack Market to Reach USD 781.52 Million by 2031 | CAGR of 4.6%
Category : Healthcare | Published Date : Nov 2024 | Type : Press Release
Transient Ischemic Attack Market Scope & Overview:
In the newly published report, Consegic Business Intelligence states that the Global Transient Ischemic Attack Market size was valued at USD 547.68 million in 2023 and is projected to register a CAGR of 4.6%, reaching USD 781.52 million by 2031. Transient ischemic attacks (TIAs), often called "mini-strokes," are brief episodes caused by temporary blood flow disruptions to the brain. Though symptoms resolve within minutes to an hour, TIAs are critical indicators of future stroke risk, necessitating immediate attention and preventive measures.
The report comprises the Transient Ischemic Attack Market Share, Size & Industry Analysis, By Type (Diagnosis (Physical Examination, Laboratory Tests, Imaging Tests, Others), Treatment (Medications, Surgery, Others)), By Age Group (Below 30 Years, 31-50 Years, Above 51 Years), By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2024-2031.
The report contains detailed information on Transient Ischemic Attack Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profile, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
Increasing prevalence of cardiovascular conditions and advancing diagnostic tools drive market growth, with innovations in surgical procedures presenting further opportunities.
Segmental Analysis :
By Type:
- Diagnosis held the largest market share in 2023, driven by the need for accurate and timely identification of TIAs, especially through advanced imaging techniques.
- Treatment is projected to grow rapidly, supported by medications like antiplatelets and anticoagulants, as well as surgical options like carotid endarterectomy for patients at high stroke risk.
By Age Group:
- Above 51 years led the market in 2023, as the risk of TIA and stroke increases with age due to factors like hypertension and atherosclerosis.
- The 31-50 years segment is expected to grow fastest, reflecting rising cardiovascular risk factors within younger demographics.
By End-User:
- Hospitals accounted for the largest share in 2023, providing comprehensive treatment with access to advanced diagnostics and multidisciplinary care.
- Ambulatory Surgical Centers are expected to see rapid growth due to their focus on same-day, minimally invasive procedures for TIA management.
Based on regions, the global market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.
- North America led the market in 2023, supported by high TIA incidence rates, advanced healthcare infrastructure, and growing awareness of stroke prevention.
- Europe is projected to grow at the highest CAGR, driven by healthcare advancements and increasing focus on early intervention.
| Report Attributes | Report Details |
| Study Timeline | 2018-2031 |
| Market Size in 2031 | USD 781.52 Million |
| CAGR (2024-2031) | 4.6% |
| By Type | Diagnosis (Physical Examination, Laboratory Tests, Imaging Tests, Others), Treatment (Medications, Surgery, Others) |
| By Age Group | Below 30 Years, 31-50 Years, Above 51 Years |
| By End-User | Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape encompasses major pharmaceutical and healthcare companies, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the Transient Ischemic Attack Industry:
- AstraZeneca (UK)
- Pfizer (U.S.)
- Sanofi (France)
- Boehringer Ingelheim International GmbH (Germany)
- Bristol-Myers Squibb Company (U.S.)
- Johnson & Johnson (U.S.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Limited (India)
- Novartis AG (Switzerland)
- Amgen Inc. (U.S.)
Recent Industry Developments :
- July 2024: Bracco Imaging and BURL Concepts announced a strategic partnership to develop advanced diagnostic tools for stroke and TIA, focusing on portable, non-invasive devices for early diagnosis.
- November 2020: AstraZeneca received US FDA approval for Brilinta (ticagrelor), indicated to reduce stroke risk in patients with acute ischemic stroke or high-risk TIA.
